Last reviewed · How we verify

HRA Pharma — Portfolio Competitive Intelligence Brief

HRA Pharma pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ella ella marketed
placebo + ethinylestradiol/levonorgestrel placebo + ethinylestradiol/levonorgestrel marketed Combined oral contraceptive Estrogen receptor and progesterone receptor Contraception / Reproductive Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Brigham and Women's Hospital · 1 shared drug class
  2. FHI 360 · 1 shared drug class
  3. Federico II University · 1 shared drug class
  4. Hansoh BioMedical R&D Company · 1 shared drug class
  5. Helsinki University Central Hospital · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. IVI Madrid · 1 shared drug class
  8. Leiden University Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for HRA Pharma:

Cite this brief

Drug Landscape (2026). HRA Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hra-pharma. Accessed 2026-05-13.

Related